155 related articles for article (PubMed ID: 38879851)
1. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives.
Vimalesvaran S; Vajro P; Dhawan A
Hepatol Int; 2024 Jun; ():. PubMed ID: 38879851
[TBL] [Abstract][Full Text] [Related]
2. Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children.
Rupasinghe K; Hind J; Hegarty R
J Pediatr Gastroenterol Nutr; 2023 Nov; 77(5):583-591. PubMed ID: 37592398
[TBL] [Abstract][Full Text] [Related]
3. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
[TBL] [Abstract][Full Text] [Related]
4. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis.
Liu J; Mu C; Li K; Luo H; Liu Y; Li Z
Int J Public Health; 2021; 66():1604371. PubMed ID: 34690666
[No Abstract] [Full Text] [Related]
5. Association of metabolic dysfunction-associated fatty liver disease with kidney disease.
Wang TY; Wang RF; Bu ZY; Targher G; Byrne CD; Sun DQ; Zheng MH
Nat Rev Nephrol; 2022 Apr; 18(4):259-268. PubMed ID: 35013596
[TBL] [Abstract][Full Text] [Related]
6. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
Flisiak-Jackiewicz M; Bobrus-Chociej A; Wasilewska N; Lebensztejn DM
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804296
[TBL] [Abstract][Full Text] [Related]
7. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD).
Roeb E
Visc Med; 2021 Aug; 37(4):273-280. PubMed ID: 34540943
[TBL] [Abstract][Full Text] [Related]
8. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
10. Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018.
Xie Z; Aimuzi R; Si M; Qu Y; Jiang Y
Front Public Health; 2023; 11():1133194. PubMed ID: 36950101
[TBL] [Abstract][Full Text] [Related]
11. A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health.
Ramírez-Mejía MM; Díaz-Orozco LE; Barranco-Fragoso B; Méndez-Sánchez N
Med Sci Monit; 2021 Aug; 27():e934134. PubMed ID: 34456329
[TBL] [Abstract][Full Text] [Related]
12. Correlation of the pediatric metabolic index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children.
Lazo-de-la-Vega-Monroy ML; Preciado-Puga MD; Ruiz-Noa Y; Salum-Zertuche M; Ibarra-Reynoso LD
Clin Res Hepatol Gastroenterol; 2023 May; 47(6):102137. PubMed ID: 37149032
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
Tang SY; Tan JS; Pang XZ; Lee GH
World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
[TBL] [Abstract][Full Text] [Related]
14. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
15. MAFLD in Obese Children: A Challenging Definition.
Di Sessa A; Guarino S; Umano GR; Arenella M; Alfiero S; Quaranta G; Miraglia Del Giudice E; Marzuillo P
Children (Basel); 2021 Mar; 8(3):. PubMed ID: 33806784
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
[TBL] [Abstract][Full Text] [Related]
17. MAFLD as part of systemic metabolic dysregulation.
Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
Hepatol Int; 2024 Apr; ():. PubMed ID: 38594474
[TBL] [Abstract][Full Text] [Related]
18. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
Liu J; Ayada I; Zhang X; Wang L; Li Y; Wen T; Ma Z; Bruno MJ; de Knegt RJ; Cao W; Peppelenbosch MP; Ghanbari M; Li Z; Pan Q
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e573-e582. PubMed ID: 33618024
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
[TBL] [Abstract][Full Text] [Related]
20. MAFLD: what 2 years of the redefinition of fatty liver disease has taught us.
Grabherr F; Grander C; Effenberger M; Schwärzler J; Tilg H
Ther Adv Endocrinol Metab; 2022; 13():20420188221139101. PubMed ID: 36439029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
